María José
García Sánchez

2024

1. An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study

   European Journal of Clinical Investigation, Vol. 54, Núm. 11

2. Analysis of apheresis outcomes in a cohort of Chilean patients treated with autologous stem cell transplantation: A single center real-world experience

   Transfusion and Apheresis Science, Vol. 63, Núm. 5

3. Clinical and molecular characterization of steatotic liver disease in the setting of immune-mediated inflammatory diseases

   JHEP Reports, Vol. 6, Núm. 10

4. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

   Therapeutic Advances in Gastroenterology, Vol. 17

5. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

   Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

6. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study

   United European Gastroenterology Journal, Vol. 12, Núm. 5, pp. 543-551

7. Desarrollo y evaluación de un modelo farmacocinético poblacional de metotrexato

   Farmajournal, Vol. 9, Núm. 1, pp. 63-71

8. Differences in circulating alpha-calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross-sectional study

   Headache, Vol. 64, Núm. 7, pp. 849-858

9. Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply

   Alimentary Pharmacology and Therapeutics

10. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 10, pp. 1248-1259

11. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

    Therapeutic Advances in Gastroenterology, Vol. 17

12. Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease

    npj Genomic Medicine, Vol. 9, Núm. 1

13. Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study

    Cephalalgia : an international journal of headache, Vol. 44, Núm. 3

14. Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply

    Alimentary Pharmacology and Therapeutics

15. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853

16. Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study

    Digestive and Liver Disease, Vol. 56, Núm. 12, pp. 2060-2068

17. Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease

    Digestive and Liver Disease, Vol. 56, Núm. 3, pp. 468-476

18. Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients

    Inflammatory Bowel Diseases, Vol. 30, Núm. 2, pp. 167-182

19. Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU

    Digestive and Liver Disease

20. Unravelling the role of beta-CGRP in inflammatory bowel disease and its potential role in gastrointestinal homeostasis

    BMC Gastroenterology, Vol. 24, Núm. 1